Gemer P 2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Pioglitazone (15mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The extended-release formulation allows for sustained drug delivery, promoting better glycemic control with reduced dosing frequency and improved patient compliance. Gemer P 2 Tablet ER is indicated for adults with type 2 diabetes inadequately controlled by diet, exercise, and monotherapy. It should be used cautiously in patients with renal or hepatic impairment and contraindicated in those with known hypersensitivity to any component, severe renal dysfunction, or diabetic ketoacidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy to optimize efficacy and minimize adverse effects such as hypoglycemia, gastrointestinal disturbances, and fluid retention.